Captor Therapeutics (WAR:CTX) Short Percentage of Float

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:CTX Captor Therapeutics SA WAR:CTX
38 GF Score
Price zł73.50
GF Value zł10.13
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Captor Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

WAR:CTX vs VRTX, REGN, ALNY: Short Percentage of Float Comparison

For the Biotechnology subindustry, Captor Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Captor Therapeutics Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Captor Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Captor Therapeutics's Short Percentage of Float falls into.


WAR:CTX
38GF Score
Captor Therapeutics SA WAR:CTX
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Captor Therapeutics (WAR:CTX) Overvalued in 2026?

Based on GuruFocus' analysis, Captor Therapeutics stock appears to be overvalued. The current stock price of zł73.50 is trading 625.6% above its estimated GF Value™ of zł10.13. GuruFocus considers Captor Therapeutics to be Significantly Overvalued.

Key valuation signals for WAR:CTX:

  • Short Percentage of Float:
  • GF Value™: zł10.13 vs. price of zł73.50 (625.6% above fair value)
  • GF Score™: 38/100 with 7 warning signs

No single metric tells the full story. See the WAR:CTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Captor Therapeutics Business Description

Address ul. Dunska 11, Wroclaw, POL, 54-427
Captor Therapeutics SA is a biopharmaceutical company. It is focused on development of protein degradation drugs for cancer and autoimmune diseases, which have limited or no known treatment options.
38GF Score

Get the complete analysis for WAR:CTX

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł73.50
Price
zł10.13
GF Value